FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.
FCGR3A
Gene polymorphism
Trastuzumab
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
21
05
2024
accepted:
09
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Breast cancer is considered a multifactorial disease, with genetic factors playing an important role in diagnosis and treatment. FCGR3A encodes the receptor for the Fc portion of immunoglobulin G that has been linked to the trastuzumab response. Our study aimed to investigate the association of FCGR3A-V158F gene polymorphism with breast cancer and to evaluate the impact of FCGR3A-V158F gene polymorphism on trastuzumab response in HER2-positive breast cancer patients. The study was conducted on eighty breast cancer patients who were collected from the Department of Oncology at Ain Shams University Hospitals; in addition, twenty age-matched healthy subjects were taken as a healthy control group. Patients were further sub-classified according to their responses. The study showed that there were no statistically significant differences between patients and controls regarding FCGR3A-V158F gene polymorphism genotypes. However, there was a significant association between the concordance of this polymorphism and the response to trastuzumab therapy among the patient's group. V/V is associated with better treatment response and overall survival (OS) compared to F/V and F/F alleles. Assessment of FCGR3A-V158F gene polymorphism might be useful in making a treatment decision in HER2-positive breast cancer patients.
Identifiants
pubmed: 39472454
doi: 10.1038/s41598-024-76024-6
pii: 10.1038/s41598-024-76024-6
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Receptors, IgG
0
FCGR3A protein, human
0
Receptor, ErbB-2
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26037Informations de copyright
© 2024. The Author(s).
Références
Wilkinson, L. & Gathani, T. Understanding breast cancer as a global health concern. Br. J. Radiol. 95(1130), 20211033 (2022).
doi: 10.1259/bjr.20211033
pubmed: 34905391
World Health Organization/International Agency for Research on Cancer: Egypt. December (2020). https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf . Accessed April 7, 2024 (2020).
Abdelaziz, A. et al. Breast Cancer awareness among Egyptian women and the impact of caring for patients with breast cancer on family caregivers’ knowledge and behaviour. Res. Oncol. 17(1), 1–8 (2021).
Schlam, I. & Swain, S. M. HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now. NPJ Breast Cancer 7(1), 56 (2021).
doi: 10.1038/s41523-021-00265-1
pubmed: 34016991
pmcid: 8137941
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 70(1), 7–30 (2020).
doi: 10.3322/caac.21590
pubmed: 31912902
Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105–117 (2023).
doi: 10.1016/S0140-6736(22)02420-5
pubmed: 36495879
Kreutzfeldt, J., Rozeboom, B., Dey, N. & De, P. The trastuzumab era: Current and upcoming targeted HER2 + breast cancer therapies. Am. J. Cancer Res. 10(4), 1045–1067 (2020).
pubmed: 32368385
pmcid: 7191090
Pandurangappa, V. et al. Assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma using image-guided clip placement. Cureus 15(10), e47763 (2023).
pubmed: 38021852
pmcid: 10679795
Huang, Y. et al. Prediction of tumor shrinkage pattern to neoadjuvant chemotherapy using multiparametric MRI-based machine learning model in patients with breast cancer. Front. Bioeng. Biotechnol. 9, 662749. https://doi.org/10.3389/fbioe.2021.662749 (2021).
doi: 10.3389/fbioe.2021.662749
pubmed: 34295877
pmcid: 8291046
Paul, P. et al. FCGR3A and FCGR2A genotypes differentially Impact Allograft rejection and patients’ Survival after Lung Transplant. Front. Immunol. 10, 1208 (2019).
doi: 10.3389/fimmu.2019.01208
pubmed: 31249568
pmcid: 6582937
Musolino, A. et al. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J. Immunother. Cancer 10(1), e003171 (2022).
doi: 10.1136/jitc-2021-003171
pubmed: 34992090
pmcid: 8739678
Nthontho, K. C. et al. Pharmacogenetics of breast cancer treatments: A sub-saharan Africa perspective. Pharmgenom. Pers. Med. 15, 613–652 (2022).
Koene, H. R. et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell fc gammaRIIIa, independently of the fc gammaRIIIa-48L/R/H phenotype. Blood 90, 1109–1114 (2022).
doi: 10.1182/blood.V90.3.1109
Mahawen,i, N. M. et al. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci. Rep. 8(1), 15983 (2018).
doi: 10.1038/s41598-018-34258-1
Gavin, P. G. et al. Association of polymorphisms in FCGR2A and FCGR3A with degree of Trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer: Analysis of the NSABP B-31 trial. JAMA Oncol. 3(3), 335–341 (2017).
doi: 10.1001/jamaoncol.2016.4884
pubmed: 27812689
pmcid: 5344747
Lassaunière, R. & Tiemessen, C. T. Variability at the FCGR locus: Characterization in Black South africans and evidence for ethnic variation in and out of Africa. Genes Immun. 17(2), 93–104 (2016).
doi: 10.1038/gene.2015.60
pubmed: 26673965
National Comprehensive Cancer Network. NCCN guidelines version 6.2020 Breast Cancer. Available online: (2020). https://education.nccn.org/ (2020).
Kuhl, C. K. et al. Validity of RECIST version 1.1 for response assessment in metastatic cancer: A prospective. Multiread. Study Radiol. 290(2), 349–356 (2019).
Rubin, E. et al. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. Int. J. Mol. Sci. 25(2), 1064 (2024).
doi: 10.3390/ijms25021064
pubmed: 38256137
pmcid: 10816365
Ramadan, M., El-Wakil, M. & Shaaban, S. Targeted treatment trastuzumab is found to greatly improve long term survival of HER2 breast cancer patients. Egypt. J. Med. Res. 1(1), 43–54 (2020).
doi: 10.21608/ejmr.2020.89043
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 22(8), 1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6 (2021).
doi: 10.1016/S1470-2045(21)00288-6
Daniyal, A., Santoso, I., Gunawan, N. H. P., Barliana, M. I. & Abdulah, R. Genetic influences in breast cancer drug resistance. Breast Cancer Dove Med. Press. 13, 59–85 (2021).
pubmed: 33603458
pmcid: 7882715
Mousa, S. M., Seifeldin, I. A., Hablas, A., Elbana, E. S. & Soliman, A. S. Patterns of seeking medical care among Egyptian breast cancer patients: Relationship to late-stage presentation. Breast 20(6), 555–561 (2011).
doi: 10.1016/j.breast.2011.07.001
pubmed: 21807518
Norton, N. et al. Association studies of Fcγ receptor polymorphisms with outcome in HER2 + breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol. Res. 2(10), 962–969 (2014).
doi: 10.1158/2326-6066.CIR-14-0059
pubmed: 24989892
pmcid: 4215796
Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789–1796 (2008).
doi: 10.1200/JCO.2007.14.8957
pubmed: 18347005
Tamura, K. et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann. Oncol. 22(6), 1302–1307 (2011).
doi: 10.1093/annonc/mdq585
pubmed: 21109570
Jacobs, S. A. et al. Correction to: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer. Breast Cancer Res. BCR 22(1), 9 (2020).
doi: 10.1186/s13058-019-1240-y
pubmed: 31969184
Hurvitz, S. A. et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin. Cancer Res. 18(12), 3478–3486 (2012).
doi: 10.1158/1078-0432.CCR-11-2294
pubmed: 22504044
Kim, J. W. et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology (Switzerland) 83(4), 218–227 (2012).
Roca, L. et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res. Treat. (3), 789–800 (2013).